Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

617.45INR
19 Dec 2014
Price Change (% chg)

Rs-3.10 (-0.50%)
Prev Close
Rs620.55
Open
Rs618.10
Day's High
Rs627.00
Day's Low
Rs615.75
Volume
45,990
Avg. Vol
159,614
52-wk High
Rs697.50
52-wk Low
Rs306.05

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.54
Market Cap (Mil.): Rs263,620.50
Shares Outstanding (Mil.): 425.02
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): 460.81 37.39 38.03
EPS (TTM): 1.35 -- --
ROI: -- 19.00 18.26
ROE: -- 19.79 19.16
Search Stocks

Nifty falls to one-month low, tracking weak China

MUMBAI - The Nifty fell for a third consecutive day on Tuesday, closing at a one-month low, as investors cashed out positions tracking a selloff in Chinese markets, hurting blue-chips such as Oil and Natural Gas Corp.

09 Dec 2014

CORRECTED-Indian shares fall to one-month low, tracking weak China

(Corrects to say shares fell for a third consecutive day, not second, in paragraph 1)

09 Dec 2014

Sun Pharma, Ranbaxy gain after regulator approves deal

Reuters Market Eye - Sun Pharmaceutical Industries gains 1.4 percent, Ranbaxy Laboratories up 2.8 percent

09 Dec 2014

CCI clears Sun Pharma-Ranbaxy deal

MUMBAI - The Competition Commission of India (CCI) approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

09 Dec 2014

MARKET EYE -India' Sun Pharma, Ranbaxy gain after regulator approves deal

** Sun Pharmaceutical Industries gains 2.9 pct, Ranbaxy Laboratories up 3.7 pct ** India's antitrust regulator approved Sun Pharma's $3.2 bln bid to buy Ranbaxy ** Approval to speed up the merger process - Traders ** Only key approval pending now is of US Federal Trade Commission, which will come in due course of time - Analysts (Reuters Messaging: abhishek.vishnoi.thomsonreuters.com@reuters.net)

09 Dec 2014

Antitrust regulator CCI clears Sun Pharma-Ranbaxy deal

MUMBAI - The Competition Commission of India (CCI) approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories , but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

India's regulator clears Sun Pharma-Ranbaxy deal

MUMBAI - India's antitrust regulator approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

UPDATE 1-India's regulator clears Sun Pharma-Ranbaxy deal

(Adds details from CCI order, comments from Sun and Ranbaxy, background)

08 Dec 2014

India's antitrust regulator clears Sun Pharma-Ranbaxy deal

MUMBAI, Dec 8 - India's antitrust regulator said on Monday it has approved generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.

08 Dec 2014

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

REUTERS - A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive.

06 Dec 2014

Earnings vs. Estimates

Search Stocks